Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
Jaume Capdevila, Virginia Pubul, Urbano Anido, Thomas Walter, Javier Molina‑Cerrillo, Teresa Alonso‑Gordoa, Rocio Garcia‑Carbonero, Maria San‑Roman‑Gil, Belen Llana, Paula Jimenez‑Fonseca, Marta Benavent Viñuales, Catherine Ansquer, Eric Baudin, Come Lepage, Maribel del Olmo‑García, José Carlos Ruffinelli, Amandine Beron, Magalie Haissaguerre, Emmanuel Deshayes, David Taïeb, Sergio Baldari, Maddalena Sansovini, Sara Cingarlini, Angelina Filice, Francesco Panzuto, Rosa Álvarez‑Álvarez, Laurence Lousberg, Frank Aboubakar Nana, Jorge Hernando, Alejando García‑Álvarez, Amparo García‑Burillo, Guillermo Villacampa, Timon Vandamme, Nicola Fazio, Alice Durand · 2026
Read Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217) by Jaume Capdevila, Virginia Pubul, Urbano Anido, Thomas Walter, Javier Molina‑Cerrillo, Teresa Alonso‑Gordoa, Rocio Garcia‑Carbonero, Maria San‑Roman‑Gil, Belen Llana, Paula Jimenez‑Fonseca, Marta Benavent Viñuales, Catherine Ansquer, Eric Baudin, Come Lepage, Maribel del Olmo‑García, José Carlos Ruffinelli, Amandine Beron, Magalie Haissaguerre, Emmanuel Deshayes, David Taïeb, Sergio Baldari, Maddalena Sansovini, Sara Cingarlini, Angelina Filice, Francesco Panzuto, Rosa Álvarez‑Álvarez, Laurence Lousberg, Frank Aboubakar Nana, Jorge Hernando, Alejando García‑Álvarez, Amparo García‑Burillo, Guillermo Villacampa, Timon Vandamme, Nicola Fazio, Alice Durand (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13264813.txt.
Description
Jaume Capdevila and a large team published a correction notice in 2026 for the LEVEL trial, a randomized study in patients with neuroendocrine tumors of the lung and thymus. The trial compares a radioactive lutetium drug against everolimus for survival and quality of life. The correction changes only the competing interests statement. It removes the line saying the remaining authors had no competing interests, and adds that one author is a co-founder, stakeholder, and chief medical officer of SILON Therapeutics. The notice states the original article has been updated.
Catalog record
| CREATOR | Jaume Capdevila, Virginia Pubul, Urbano Anido, Thomas Walter, Javier Molina‑Cerrillo, Teresa Alonso‑Gordoa, Rocio Garcia‑Carbonero, Maria San‑Roman‑Gil, Belen Llana, Paula Jimenez‑Fonseca, Marta Benavent Viñuales, Catherine Ansquer, Eric Baudin, Come Lepage, Maribel del Olmo‑García, José Carlos Ruffinelli, Amandine Beron, Magalie Haissaguerre, Emmanuel Deshayes, David Taïeb, Sergio Baldari, Maddalena Sansovini, Sara Cingarlini, Angelina Filice, Francesco Panzuto, Rosa Álvarez‑Álvarez, Laurence Lousberg, Frank Aboubakar Nana, Jorge Hernando, Alejando García‑Álvarez, Amparo García‑Burillo, Guillermo Villacampa, Timon Vandamme, Nicola Fazio, Alice Durand |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 1584 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |